Medtronic plc reported revenue of $9.76B for the period ended 2026-07-31, +13.7% year on year. Net income was $1.47B, a 15.1% net margin on a 65.0% gross margin. The largest revenue line is Neuroscience Group at 27% of the total. Free cash flow for the period was $1.29B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $9.76B | +13.7% |
| Gross profit | $6.34B | — |
| Operating income | $1.76B | — |
| Net income | $1.47B | +41.3% |
| Gross margin | 65.0% | Net margin 15.1% |
| Segment | Revenue | Share |
|---|---|---|
| Neuroscience Group | $2.68B | 27.4% |
| Medical Surgical | $2.28B | 23.4% |
| Electrophysiology Therapies Division | $2.22B | 22.7% |
| Interventional Cardiology Therapies Division | $0.89B | 9.2% |
| Diabetes Group | $0.84B | 8.6% |
| Cardio Vascular Surgery Division | $0.48B | 4.9% |
| Peripheral Vascular Health Division | $0.34B | 3.5% |
| Other Operating Segment Misc | $0.03B | 0.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $3.42B | 35.0% |
| SG&A | $3.20B | 32.8% |
| Tax & other | $0.29B | 3.0% |
| Item | Amount |
|---|---|
| Total assets | $93.31B |
| Total liabilities | $42.46B |
| Shareholders' equity | $50.85B |
| Equity / assets | 54.5% |
| Operating cash flow | $1.79B |
| Capital expenditure | $0.50B |
| Free cash flow | $1.29B |
| Cash conversion (OCF / net income) | 122% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
MRK ・ META ・ MET ・ MTD ・ MGM ・ MCHP ・ MU ・ MSFT ・ MAA ・ MRNA ・ TAP ・ MDLZ
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies